Indication I
Therapy: FDA-designated GRAS small molecules and four AI-engineered BBB-traversing peptides to treat Alzheimer’s identified and established. Animal and human brain organoid studies completed.
Status: Preclinical, first-in-class therapy to reverse both early and late stage Alzheimer’s and to reduce phosphor-Tau release, an FDA approved AD biomarker. Molecular underpinnings of the two small molecules and the four peptide drugs have been determined.
Commercial Value: An FDA-approved Alzheimer's drug holds massive commercial value, with market estimates exceeding $43 billion for top-tier treatments.